v3.25.0.1
Stock-based compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense Recorded in Consolidated Statements of Operations

Stock-based compensation is classified as follows in the accompanying consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

Cost of revenues, genomics

 

$

13,625

 

 

$

—

 

 

$

—

 

Cost of revenues, data and services

 

 

8,530

 

 

 

—

 

 

 

—

 

Technology research and development

 

 

58,473

 

 

 

—

 

 

 

—

 

Research and development

 

 

47,638

 

 

 

—

 

 

 

—

 

Selling, general and administrative

 

 

405,872

 

 

 

—

 

 

 

—

 

Total stock-based compensation

 

$

534,138

 

 

$

—

 

 

$

—

 

Schedule of the activity related to the Company's RSUs

The table below summarizes restricted stock unit activity for the year ended December 31, 2024:

 

 

 

Restricted Stock Units

 

 

Weighted - Average Grant Date
Fair Value

 

Unvested at December 31, 2023

 

 

20,788,500

 

 

$

26.47

 

Granted

 

 

4,020,190

 

 

$

39.75

 

Vested and settled

 

 

(12,143,140

)

 

$

19.95

 

Vested and not yet settled

 

 

(4,772,362

)

 

$

37.87

 

Forfeited

 

 

(871,838

)

 

$

35.97

 

Expired

 

 

(147,376

)

 

$

0.28

 

Unvested at December 31, 2024

 

 

6,873,974

 

 

$

38.23

 

Schedule of Stock Options

 

 

Number of Options

 

 

Exercise Price Ranges

 

 

Weighted-Average Exercise Price

 

Outstanding at December 31, 2023

 

 

210,000

 

 

$

0.85

 

 

$

0.85

 

Granted

 

 

—

 

 

$

—

 

 

$

—

 

Exercised

 

 

(210,000

)

 

$

0.85

 

 

$

0.85

 

Forfeited

 

 

—

 

 

$

—

 

 

$

—

 

Outstanding at December 31, 2024

 

 

—

 

 

$

—

 

 

$

—

 

Options exercisable at December 31, 2024

 

 

—

 

 

$

—

 

 

$

—

 

 

Schedule of Restricted Stock Awards

 

 

Restricted

 

 

Unrestricted

 

 

Total

 

 

Weighted - Average Grant Date Fair Value

 

Balance at December 31, 2023

 

 

—

 

 

 

4,250,000

 

 

 

4,250,000

 

 

$

0.42

 

Converted into Class A voting common stock

 

 

—

 

 

 

(4,250,000

)

 

 

(4,250,000

)

 

$

0.42

 

Balance at December 31, 2024

 

 

—

 

 

 

—

 

 

 

—

 

 

$

—